Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations
about
sameAs
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)Causes and consequences of the autoimmune lymphoproliferative syndromeFas-mediated apoptosis regulates the composition of peripheral alphabeta T cell repertoire by constitutively purging out double negative T cellsDistinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in ZambiaDiagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay.Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytesNovel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice.Targeting Notch signaling in autoimmune and lymphoproliferative disease.Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
P2860
Q24623371-26D66172-43E5-45D8-880C-B4214EB1191BQ24643047-94A74BF0-CAB9-4404-8278-AF4133FC066FQ24685850-A7FF751A-AC02-4ACD-BFA6-D417F10B7817Q28300792-059859B6-08CE-4A55-9A5E-6EA05AAF3EE7Q33378507-621252E2-12CA-4BC6-9719-F9FA642A556BQ33393958-53109675-6A8F-4678-A0E1-B38B009CFD12Q33614310-1519AADE-E0AD-404F-84B5-B673EF85C50AQ34513178-6C4B06DA-5434-4BD3-9104-9F2EDEAC14DCQ36166651-57EB5D16-48A7-43A7-805B-3FA273A05E1BQ37248354-633BDC15-90C2-427D-A951-6D6BDAE4D48AQ38823961-E1EAB9AF-3C09-421B-B16F-814F69E92E5BQ41943841-F0229BE0-D543-4CE4-89ED-E978A4A5266AQ42953771-FA5F0FB0-E20C-40AD-A7B2-C454E17AF8B1Q53316605-D0A23779-FE95-44FD-B2FA-DAC6D38714C3
P2860
Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Reversion of autoimmune lympho ...... udy and molecular observations
@ast
Reversion of autoimmune lympho ...... udy and molecular observations
@en
Reversion of autoimmune lympho ...... udy and molecular observations
@nl
type
label
Reversion of autoimmune lympho ...... udy and molecular observations
@ast
Reversion of autoimmune lympho ...... udy and molecular observations
@en
Reversion of autoimmune lympho ...... udy and molecular observations
@nl
prefLabel
Reversion of autoimmune lympho ...... udy and molecular observations
@ast
Reversion of autoimmune lympho ...... udy and molecular observations
@en
Reversion of autoimmune lympho ...... udy and molecular observations
@nl
P2093
P2860
P3181
P1476
Reversion of autoimmune lympho ...... udy and molecular observations
@en
P2093
Alice Ferster
Christian Demanet
Geneviève Laurey
Jacques Otten
Jutte van der Werff Ten Bosch
Kris Thielemans
Mikko Arola
Nadira Azzi
Peter Schotte
Rudi Beyaert
P2860
P304
P3181
P356
10.1046/J.1365-2141.2002.03357.X
P407
P577
2002-04-01T00:00:00Z